丙肝治愈后FIB-4变化可预测肝癌发生风险
研究纳入3823例直接抗病毒治疗获持续病毒学应答的丙肝患者,在SVR24及之后1、2、3年测FIB-4并随访肝癌发生。结果显示持续FIB-4>3.25者肝癌发生率显著高于降至≤3.25者(4年16.0% vs 4.4%,P<.001),调整后风险比最高3.38。提示重复评估FIB-4可识别需加强肝癌监测的高危人群。
要点
- SVR后持续FIB-4>3.25者肝癌风险显著升高,4年发生率16.0%
- FIB-4降至≤3.25者4年肝癌发生率仅4.4%
- SVR后重复评估FIB-4可识别需强化肝癌监测的高危患者
核心结论
- FIB-4可在SVR后任何时间点评估肝癌发生风险,其变化与肝癌风险变化相关。
研究设计与样本
- 回顾性队列研究,纳入3823例接受直接抗病毒治疗并获持续病毒学应答的丙肝患者。
- 在SVR24及之后1、2、3年测FIB-4,随后调查肝癌发生情况。
主要发现
- SVR24及之后1、2、3年FIB-4>3.25者,后续肝癌发生均显著高于同期FIB-4≤3.25者。
- 持续FIB-4>3.25者SVR24后1、2、3、4年肝癌发生率分别为5.4%、9.2%、11.7%、16.0%,显著高于降至≤3.25者的2.2%、3.1%、3.7%、4.4%(P<.001)。
- SVR24及之后1、2、3年FIB-4>3.25的调整风险比(95%CI)分别为3.38(2.4-4.8)、2.95(1.9-4.7)、2.62(1.3-5.1)、3.37(1.4-9.8)。
关键数值与推荐
- FIB-4阈值3.25用于定义持续高纤维化风险。
- 持续FIB-4>3.25者4年肝癌累积发生率16.0%,降至≤3.25者4.4%。
临床怎么用
- 丙肝SVR后应重复评估FIB-4,持续>3.25者归为肝癌高危人群。
- 对持续FIB-4>3.25者考虑更密集的肝癌监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether the fibrosis 4 index (FIB-4), a marker of liver fibrosis, at baseline and change in FIB-4 after sustained virological response (SVR) is associated with incident hepatocellular carcinoma (HCC) risk. In this study, we examined the association of incident HCC risk with baseline FIB-4 and sustained high FIB-4 (>3.25) at any time point after SVR. METHODS: A total of 3823 patients who received direct-acting antiviral treatment and achieved SVR were enrolled. The FIB-4 was measured 24 weeks after the end of direct-acting antiviral treatment and achievement of SVR (SVR24), and 1, 2, and 3 years after SVR24, after which subsequent HCC development was investigated. RESULTS: In patients with an FIB-4 >3.25 at SVR24 and 1, 2, and 3 years after SVR24, subsequent HCC development was significantly higher than in those with an FIB-4 ≤3.25 at each point. The rates of HCC development 1, 2, 3, and 4 years after SVR24 were significantly higher in patients with sustained FIB-4 >3.25 than in those whose FIB-4 decreased to ≤3.25 (5.4%, 9.2%, 11.7%, and 16.0%, respectively, vs 2.2%, 3.1%, 3.7%, and 4.4%; P < .001). The adjusted hazard ratios (95% confidence intervals) for an FIB-4 >3.25 at SVR24 and 1, 2, and 3 years later were 3.38 (2.4-4.8), 2.95 (1.9-4.7), 2.62 (1.3-5.1), and 3.37 (1.4-9.8), respectively. CONCLUSIONS: The FIB-4 could be used to assess HCC development risk at any time after SVR, and changes in FIB-4 were associated with changes in the HCC development risk. Repeated assessments of FIB-4 could serve as a prognostic indicator of a high-risk HCC cohort that may require more intensive HCC surveillance strategy.
引用
- Tamaki N, Kurosaki M, Yasui Y, et al. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clin Infect Dis. 2021. PMID: 33544129. doi:10.1093/cid/ciaa1307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。